摘要
目的:研究益气活血中成药治疗心肌梗死随机对照试验的系统评价。方法:选择2015年1月-2016年2月于我院就医的急性心肌梗死且实行溶栓治疗病患82例,所有患者均在入院进行前全面检查,进行病情确诊,且签署手术同意书,随机将其均分为研究组与参考组,各组患者均为41例,其中参考组采用注射用阿替普酶(n-PA)溶栓治疗,而研究组则在以上基础上配合口服活血胶囊进行治疗,病情稳定后行冠状动脉造影术对比各组患者的冠状动脉再通情况,计算冠状动脉再通率。结果:根据本次研究结果显示,在治疗效果对比方面,研究组4l例患者冠状动脉再通率为92.68%;而参考组41例患者冠状动脉再通率为75.61%;以上组间数据对比存在显著差异,满足统计学意义(P<0.05)。结论:同单纯溶栓药物治疗,以溶栓治疗配合口服活血中成药能够显著提升对急性心肌梗死临床治疗效果,具有临床推广意义。
Objective:A systematic review of Yiqi Huoxue TCM patent medicine on myocardial infarction.Methods:82patients werein the hospital for full inspection before,to carry on the diagnosis,and sign the operation agreement,and were divided into research groupand reference group,41cases in each.The control took atenolol injection at enzyme(rt-PA)thrombolysis therapy,and the treatment grouptook huoxue capsule treatment more.Results:The results of this study shows that in the treatment group41patients of coronary arteryrevovering rate is92.68%;in another group it was75.61%,P<0.05.Conclusion:Huoxue Huayu TCM patent medicines can significantlyenhance the clinical treatment of acute myocardial infarction.
出处
《中医临床研究》
2017年第12期30-31,共2页
Clinical Journal Of Chinese Medicine
关键词
中成药
心肌梗死
临床疗效
TCM medicines
Myocardial infarction
Clinical efficacy
